Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics
A new report from Healthcare Market Research Reports has been published that explores the market potential related to diagnostic, monitoring, and screening test opportunities for circulating tumor cell, cell-free DNA, and exosome/microvesicle cancer diagnostics by lung, breast, colorectal, prostate, and other cancers. The report projections are for the years 2017-2020.
The report posits that a revolution in cancer diagnostics is occurring, specifically referring to the use of in vitro blood testing to identify cancer DNA.
McKesson Ventures portfolio company GRAIL is highlighted for its single blood test to detect all cancers, a technology that is rapidly developing. When successful, this technology could replace expensive and invasive surgical biopsy procedures with a simple blood test.
Read more about the market forecast here.